Gastro-oesophageal Reflux Disease Trial, Recruiting NCT03418350 Sponsor: National Jewish Health Condition: Gastro-oesophageal Reflux Disease
Back to Gord

Gastro-oesophageal Reflux Disease Trial, Recruiting

NCT03418350
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with IPF (idiopathic pulmonary fibrosis, a lung condition causing scarring)
  • People aged between 40 and 95 years old
  • People who are able to read, speak, and understand English
  • People who take medication for acid reflux or GERD (gastroesophageal reflux disease) must have been on a stable, unchanged dose for at least 4 weeks before signing the consent form

Who may not be able to join:

  • People who do not meet all of the above criteria
  • People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Matthew Koslow, DO, National Jewish Health

Phone: 303-398-1996

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
National Jewish Health
Registry
ClinicalTrials.gov
Start date
1 August 2018
Est. completion
1 December 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

The supraglottic index (SGI) quantifies laryngopharyngeal reflux (LPF) and is associated with severity of pulmonary fibrosis.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov